These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28111042)

  • 41. Immune checkpoint blockade therapy for bladder cancer treatment.
    Kim J
    Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S98-S105. PubMed ID: 27326412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
    Barclay J; Creswell J; León J
    Arch Esp Urol; 2018 May; 71(4):393-399. PubMed ID: 29745928
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
    Schmidinger M
    Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
    Shah S; Ward JE; Bao R; Hall CR; Brockstein BE; Luke JJ
    Cancer Immunol Res; 2016 Nov; 4(11):903-909. PubMed ID: 27638840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis.
    Necchi A; Raggi D; Giannatempo P; Sonpavde G; Galsky MD; Bellmunt J; Mariani L; Miceli R
    Clin Genitourin Cancer; 2017 Oct; 15(5):509-512.e9. PubMed ID: 28478885
    [No Abstract]   [Full Text] [Related]  

  • 47. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
    Callea M; Pedica F; Doglioni C
    Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biennial report on genitourinary cancers.
    Fizazi K
    Eur J Cancer; 2016 Oct; 66():125-30. PubMed ID: 27569040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Harnessing Natural Killer Cell Function for Genitourinary Cancers.
    Bhardwaj N; Farkas AM; Gul Z; Sfakianos JP
    Urol Clin North Am; 2020 Nov; 47(4):433-442. PubMed ID: 33008494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent developments in the treatment of advanced bladder cancer.
    Godwin JL; Hoffman-Censits J; Plimack E
    Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunologic features of genitourinary cancer.
    Javadpour N
    Urology; 1973 Aug; 2(2):103-8. PubMed ID: 4129366
    [No Abstract]   [Full Text] [Related]  

  • 52. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers.
    Gill DM; Agarwal N
    Urol Oncol; 2017 Dec; 35(12):676-677. PubMed ID: 29054496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.
    Grasselly C; Denis M; Bourguignon A; Talhi N; Mathe D; Tourette A; Serre L; Jordheim LP; Matera EL; Dumontet C
    Front Immunol; 2018; 9():2100. PubMed ID: 30356816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
    Yang HY; Sun LJ; Mao YL
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
    [No Abstract]   [Full Text] [Related]  

  • 56. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma.
    Hsu FS; Su CH; Huang KH
    J Immunol Res; 2017; 2017():6940546. PubMed ID: 29376081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
    Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combinations of Bevacizumab With Cancer Immunotherapy.
    Chen DS; Hurwitz H
    Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.